Latest research on Duloxetine

Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.

Latest findings

Analyses made on the subgroup of fluoxetine studies (where the number of analysed patients was greater than 20), gave for the efficacy 0.09 [-0.09;0.26] (13 fluoxetine studies) still favouring fluoxetine, for the response factor -0.22 [-0.46;0.02] (10 fluoxetine studies) still favouring Duloxetine and for the dropouts factor -0.02 [-0.33;0.28] (7 fluoxetine studies) similar results were found. [source, 2006]
For Duloxetine compared with Venlafaxine, cf. [source, 2006]
The use of the meta-regression method to indirectly compare Duloxetine with each active comparator revealed that there was no significant difference with fluoxetine either in efficacy or in safety. [source, 2006]
Findings only suggest that more patients might respond to Duloxetine. [source, 2006]
Results suggest that Duloxetine might be significantly less effective compared with Venlafaxine, (in terms of treatment effects and number of response) with similar dropouts rates. [source, 2006]
The results became nonsignificant in one analysis comparing Venlafaxine with Duloxetine, but the estimated value seldom moved. [source, 2006]
When removing [4] or [5] from the analysis set, Duloxetine treated patients had statistically more chance to respond than when treated with fluoxetine. [source, 2006]
These findings were obtained by removing the less favourable studies for Duloxetine, and we found no differences in the design or patients' characteristics that may explain why. [source, 2006]
These tests showing significance (when comparing fluoxetine to Duloxetine) or non-significance (when comparing Venlafaxine to Duloxetine), as in every study where multiple testing is performed, may be due to a drop in statistical power, which can bias the conclusions. [source, 2006]
While we recognize that none of the trials involving Duloxetine used Venlafaxine as an active comparator, our results are in accordance with a recent meta-analysis comparing Duloxetine and Venlafaxine in the treatment of MDD [45] and a review comparing second-generation antidepressants [46]. [source, 2006]